The application of platelet-rich plasma in the treatment of knee osteoarthritis: A literature review

Academy of Orthopedics, Department of Orthopedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China. Academy of Orthopedics, Department of Orthopedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China; Department of Histology and Embryology, School of Basic Medical Science, Southern Medical University, Guangzhou, China. Academy of Orthopedics, Department of Orthopedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China. Electronic address: 13802408767@163.com.

Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association. 2021
Full text from:
Abstract
BACKGROUND Primary knee osteoarthritis remains a difficult-to-control degenerative disease. With the rise in average life expectancy and the incidence of obesity, osteoarthritis has brought an increasing economic and physical burden on people. This article summarizes the latest understanding of platelet-rich plasma in the treatment of knee osteoarthritis, and reviews the economic issues of PRP. METHODS The literatures in Pubmed, Embase, Cochrane library, Web-science and other databases were searched, and literature inclusion and exclusion criteria were formulated. According to the Cochrane systematic reviewer's manual, the included literatures were grouped, and qualitative descriptions and quantitative meta-analysis were performed. Continuous statistical methods were used to compare the effects and adverse effects of PRP before and after treatment, as well as between PRP and other conservative treatments. RESULTS A total of 12 randomized controlled trials were included in this study. A total of 959 KOA patients (1070 knees) were enrolled and followed for 3-12 months. PRP total knee scores were significantly better than baseline at 1, 2, 3, 6 and 12 months after treatment (1 month: SMD = 0.60, P < 0.01; 2 months: SMD = 0.98, P < 0.01; 3 months: SMD = 1.16, P < 0.01; 6 months: SMD = 1.49, P < 0.01; 12 months: SMD = 1.47, P < 0.01). In terms of adverse reactions, PRP did not increase the risk of adverse events compared with HA (OR = 0.96, P = 0.85). CONCLUSIONS Compared with many other treatment methods, intra-articular injection of PRP has been proven to be safe and effective to improve the quality of life of patients with KOA.
Study details
Study Design : Systematic Review
Language : eng
Credits : Bibliographic data from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine